Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

N/ANot Yet RecruitingNCT07604220

Mayo Clinic115 enrolled

Overview

The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.

Study Type

OBSERVATIONAL

Enrollment

115

Conditions

Cardiac Sarcoidosis Sarcoidosis of the Heart Sarcoidosis With Myocarditis Sarcoidosis, Cardiac

Interventions

Exosome AnalysisOTHER

Blood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Adults ≥18 years. * Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis. * Undergoing FDG-PET as part of standard care. * Ability to provide informed consent. Exclusion Criteria • Inability to provide informed consent.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Number of successful biomarker validations

Biomarker validation will be defined as ability to discriminate active from inactive or quiescent disease as assessed by FDG-PET

Time frame: Baseline

Central Contacts

Anna Pick

CONTACT

507-255-0630 pick.anna@mayo.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.